ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'

FDA is again relying on sponsor self-reporting as it launches GDUFA II.

FDA again will by relying on industry prior to GDUFA II's launch to ensure new user fees are correct. In this case, it's the ANDA holder fee, which was created for the reauthorization of the Generic Drug User Fee Act in part to provide a break for small businesses. It is based on the number of approved ANDAs a sponsor and its affiliates own.

To ensure FDA has the most accurate information on ANDA owners and their affiliates, the agency plans to publish its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.